Cue Biopharma Director Pamela Garzone Receives 18,900-Share Award

What Happened

• Pamela Garzone, a director of Cue Biopharma, received a grant of 18,900 restricted stock units (RSUs) on July 9, 2026. The grant was reported at $0.00 per share (typical for RSU awards), so no cash changed hands. These RSUs vest one-third on each of July 9, 2027, July 9, 2028 and July 9, 2029, contingent on continued service.

Key Details

• Transaction type: Award/Grant (RSUs)
• Transaction date: July 9, 2026; filing amended on August 28, 2026
• Price: $0.00 per share (non-cash compensation)
• Shares acquired: 18,900 RSUs (corrected from 21,800 in the original filing)
• Shares beneficially owned after transaction: 18,900
• Vesting: One-third vests each year on Jul 9 of 2027, 2028 and 2029, subject to continued service
• Filing note: This is an amended Form 4 correcting an administrative calculation error in the original filing (overstated shares)

Context

• RSU grants are standard compensation and do not reflect an open-market purchase or sale; they vest over time and become taxable when vested/settled. The amendment merely corrects the number of RSUs granted and the resulting beneficial ownership figure.